Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors

M Zimmer, D Doucette, N Siddiqui, O Iliopoulos - Molecular Cancer Research, 2004 - AACR
M Zimmer, D Doucette, N Siddiqui, O Iliopoulos
Molecular Cancer Research, 2004AACR
Abstract The von Hippel-Lindau tumor suppressor protein (pVHL) is a substrate receptor for
the mammalian SCF-2 E3 ubiquitin ligase complex that targets several substrates for
ubiquitination and proteasomal degradation. Among these targets are the α-regulatory
subunits of the hypoxia-inducible factor (HIF). VHL−/− cells constitutively overexpress
hypoxia-inducible genes through both transcriptional and posttranscriptional mechanisms
and form tumors when injected into nude mice. Reintroduction of pVHL into VHL−/− cell …
Abstract
The von Hippel-Lindau tumor suppressor protein (pVHL) is a substrate receptor for the mammalian SCF-2 E3 ubiquitin ligase complex that targets several substrates for ubiquitination and proteasomal degradation. Among these targets are the α-regulatory subunits of the hypoxia-inducible factor (HIF). VHL−/− cells constitutively overexpress hypoxia-inducible genes through both transcriptional and posttranscriptional mechanisms and form tumors when injected into nude mice. Reintroduction of pVHL into VHL−/− cell lines restores normal oxygen-dependent regulation of these genes and suppresses tumor formation in the mouse xenograft assay. We report here that short hairpin RNA-mediated inactivation of HIF phenocopies the effects of pVHL reintroduction with respect to decreased expression of hypoxia-inducible genes, decreased ability to promote vascular endothelial cell proliferation in vitro, and tumor growth suppression in vivo. In addition, HIF inactivation abrogated the cellular response to hypoxia, indicating that HIF is the only pVHL target required for this response. These data suggest that deregulation of hypoxia-inducible genes in VHL−/− cells can be attributed mainly to deregulation of HIF and validate HIF as a therapeutic anticancer drug target.
AACR